department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Ddavp · pharmadog

pharmadog
drugs
Ddavp

drug

patient view →

desmopressin acetate

Marketedupdated 2mo ago

by Ferring Pharmaceuticals Inc

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

all catalysts(1)

approval · 1

DESMODA (DESMOPRESSIN ACETATE) — FDA approval

desmopressin acetate

News(0)

no news has mentioned this drug yet

brand

Ddavp

generic

desmopressin acetate

MOA

12.1 Mechanism of Action Desmopressin acetate’s primary pharmacodynamic action involves its binding to vasopressin 2 (V2) receptors. V2 receptors are primarily located in the distal convoluted tubule and collecting ducts of the nephron in the kidneys. These receptors play a crucial role in regulating water reabsorption and urine concentration. By influencing the permeability of the renal tubules, V2 receptors help maintain the body’s water balance and overall homeostasis.

indication

Diabetes Insipidus

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

May 21, 2029

~2.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Apr 3, 2044formulationUS 12214010
Apr 3, 2044formulationUS 12343372
Jun 15, 2030method-of-use (U-3431)US 114199143.9y
Jun 15, 2030method-of-use (U-3431)US 114199143.9y
Jun 15, 2030formulationUS 120901903.9y
Jun 15, 2030formulationUS 120901903.9y
Jun 15, 2030formulationUS 95393023.9y
Jun 15, 2030formulationUS 95393023.9y
Apr 13, 2030method-of-use (U-2326)US 99748263.8y
Apr 13, 2030method-of-use (U-2327)US 99748263.8y
May 21, 2029method-of-use (U-2327)US 101371672.9y
May 21, 2029method-of-use (U-2327)US 110204482.9y
May 21, 2029method-of-use (U-2327)US 119639952.9y
May 21, 2029method-of-use (U-2327)US 119639952.9y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$ETON38.02+1.39%

🐶 often sniffed alongside

top 5

tagApproval4 co-mentions · 2 sources
drugDESMODA4 co-mentions · 3 sources
companyApotex Corp1 co-mentions · 1 sources
tagSmall Molecule1 co-mentions · 1 sources
tagDrug Shortage1 co-mentions · 1 sources